Dionysus Health Debuts Predictive Test for Postpartum Depression
Postpartum depression is the number one complication of childbirth, affecting up to 1 in 4 women, yet no standard test exists to predict it. After a decade of innovation, Dionysus Health is emerging from stealth to help solve this crisis.
Our first breakthrough: The first commercially available biological test to predict a woman’s risk of developing postpartum depression uses a simple third-trimester blood draw, enabling early detection and proactive care before symptoms begin. No waiting until it’s too late. Finally, a clinically validated diagnostic that’s redefining maternal care with proactive diagnosis and treatment.
Accelerating with breakthrough science, national recognition, and strong investor interest.
- Secured $15M in non-dilutive funding, including award from NIH
- Awarded $10M from the DoD to support clinical validation and our FDA approval pathway
- Launching three commercial pilots in Q4 2025
- Defined a clear path to FDA clearance by 2027
- Continue to be recognized by the market
- 2025 Springboard Cohort
- 2025 Connect Cool Company Winner
- 2025 Femovate Recipient
- 2024 OneMind Accelerator Cohort
- 2024 Ignite Golden Ticket Winner
- 2024 ADLM Disruptive Technology Finalist
- 2024 NIH RADx Finalist
For more information about Dionysus Health, visit dionysushealth.com and follow them on LinkedIn
For more information on Femovate visit www.femovate.com and follow us on LinkedIn
For interviews please contact Theresa Neil
